Redeye returns with a comment after the conference call on the EUR115m licensing deal yesterday. We have updated our model with a lower WACC, thanks to the significantly reduced dilution risk, resulting in a restatement of our base case of SEK85, despite estimated lower peak sales in kidney transplantation and AMR.
LÄS MER
